Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Choby

Physician Assistant, Medical Stuart, FL Physician Assistant

NPI 1578955118 CMS profile 11222018

301 Se Ocean Blvd Ste 102, Stuart, FL 34994

Open in the dashboard

General payments

$15,828

853 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Choby of Stuart, FL is reported in the CMS Open Payments database as having received $15,828 across 853 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,767 246
2024 General $3,579 183
2023 General $3,787 210
2022 General $2,824 164
2021 General $870 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Choby
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Elizabeth Choby were reported at $4,767. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Elizabeth Choby Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $870 $156 $41–$563 $132
2022 $2,824 $185 $55–$649 $149
2023 $3,787 $199 $58–$717 $160
2024 $3,579 $206 $62–$740 $164
2025 $4,767 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Incyte Corporation $1,342 68 payments
  2. Celgene Corporation $1,270 98 payments
  3. Janssen Biotech, Inc. $1,250 64 payments
  4. Novartis Pharmaceuticals Corporation $1,243 68 payments
  5. Pfizer Inc. $1,059 74 payments
  6. AstraZeneca Pharmaceuticals LP $965 51 payments
  7. Genzyme Corporation $800 38 payments
  8. Merck Sharp & Dohme Corporation $755 36 payments
  9. Seattle Genetics, Inc. $415 22 payments
  10. Daiichi Sankyo Inc. $392 20 payments
  11. Other $6,336 314 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,608 850 payments
  2. Education $220 3 payments
Products named General payments · program years 2021–2025
  1. JAKAFI $944 55 payments
  2. KEYTRUDA $755 36 payments
  3. REBLOZYL $715 47 payments
  4. DARZALEX $556 27 payments
  5. SARCLISA $536 23 payments
  6. KISQALI $509 28 payments
  7. TUKYSA $469 37 payments
  8. PLUVICTO $402 19 payments
  9. IBRANCE $397 36 payments
  10. Pomalyst $346 31 payments
  11. Other $13,322 703 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

329

Median for Physician Assistant: 241

Drug cost

$514,107

Median for Physician Assistant: $4,110

Branded share of claims

25.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 12 $204,425
Jakafi Ruxolitinib Phosphate Brand 12 $158,852
Calquence Acalabrutinib Maleate Brand 11 $136,946
Eliquis Apixaban Brand 15 $8,789
Ondansetron Hcl Generic 17 $1,565
Megestrol Acetate Generic 11 $653
Hydroxyurea Generic 15 $566
Letrozole Generic 25 $469
Prochlorperazine Maleate Generic 19 $444
Anastrozole Generic 21 $382

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 74 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JAKAFI
  • Incyte Corporation $204
$204 12 —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $173
$173 — —
Padcev
  • PFIZER INC. $101
  • Astellas Pharma US Inc $45
$147 — —
PLUVICTO
  • Novartis Pharmaceuticals Corporation $144
$144 — —
SARCLISA
  • GENZYME CORPORATION $142
$142 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 74 with Patron

Records

853 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record